ALKEM

Alkem Laboratories – News & Updates Medical device expansion Alkem’s subsidiary has signed an agreement to acquire a majority stake in Switzerland-based Occlutech, a medical device company. This marks Alkem’s entry into the global structural heart device market and diversification beyond pharmaceuticals. Recent quarterly performance The company reported steady revenue growth in FY26, supported by strong domestic branded formulations and improving international sales. Profitability remained healthy due to better product mix and cost control. USFDA inspection update The USFDA inspected the Enzene Biosciences facility, a subsidiary of Alkem. The inspection resulted in a few procedural observations but no major compliance issues. Dividend announcement The company announced a large interim dividend of ₹43 per share, reflecting strong cash flows and balance sheet strength. Stock movement The stock has seen short-term volatility recently, reacting to broader pharma sector movements and regulatory updates. Overall outlook Positives: strong domestic pharma franchise, consistent earnings, diversification into medical devices. Risks: regulatory inspections, US generics pricing pressure, and pharma sector competition.